will be an invasion and it will come soon. I am thinking Saturday--yes, this upcoming Saturday. The Houthis (all 9 millions of them) and their Iranian alley will not back down so easily. Just my opinion. And, by the way, I am long UCO which moves double that of USO in case of an invasion. I welcome a constructive conversation. GLTA
mark this post if you are a shorty. LOL
sooner than well think. IMHO and GLTA
Mydicar could be a game-changing cardiovascular gene therapy
Mydicar is a gene therapy that targets the SERCA2a enzyme deficiency in patients suffering from heart failure. Given that SERCA2a levels have been shown to be strongly correlated with heart function in terms of the amount of blood it can pump, this enzyme has become a prominent therapeutic target in gene therapy studies.
The basic idea is to use gene therapies such as Mydicar to restore SERCA2a enzyme levels to normal, which should, in turn, result in fewer hospitalizations and deaths stemming from this devastating disease. As there are no curative treatments for heart failure and the currently approved drugs are used only to alleviate symptoms, Mydicar is, without question, a potential game-changer.
That's why the Food and Drug Administration granted Mydicar the coveted breakthrough therapy designation last April, meaning that it could be approved early based on the upcoming mid-stage results. And indeed, Celladon has already begun ramping up production levels to support a commercial launch in the near future.
How risky is this clinical-stage biotech?
This pending data readout is going to be a make-or-break moment for Celladon, given that its entire platform is based on Mydicar's technology that has taken approximately 20 years to develop. But there are some fairly strong reasons to be optimistic going forward.
First off, the mid-stage trial in question, dubbed CUPID-2, is largely a scaled up version of an earlier trial (CUPID-1) that was stunningly successful in several respects. Chief among them, the 39 patient CUPID-1 trial showed that Mydicar treatment led to significantly lower rates of hospitalizations and deaths, even three years after treatment, when compared to patients receiving placebo. Another key finding was that patients receiving Mydicar experienced no negative side effects over the three-year follow-up period.
According to the company, the CUPID-2 trial is highly similar in terms of pati
Could This Clinical-Stage Biotech Stock Soar in April?
By Motley Fool, March 12, 2015, 08:59:01 AM EDT
Biotech stocks are known for their wild ways. Over the last few years, for instance, we have witnessed dozens of small-cap companies soar -- as well as sink -- following pivotal clinical or regulatory catalysts.
Perhaps one of the most intriguing aspects of this phenomenon is that the biggest moves tend to occur in under-the-radar biotechs. Before skyrocketing by over 300% in just two days last year, for example, Intercept Pharmaceuticals was known only to a handful of analysts and investors. And similar cases could be made for the cancer drugmaker InterMune and gene therapy company bluebird bio prior to their huge moves upwards.
That's why I find the case for Celladon Corporation particularly intriguing. This small-cap cardiovascular gene therapy company is expected to release mid-stage results for its flagship heart failure treatment, Mydicar, next month. And despite the therapy's initial indication for systolic heart failure estimated to generate peak sales in excess of $1.5 billion by 2025, the stock has attracted little attention from the broader market.
Celladon shares, though, have been heating up over the past few days, with the stock jumping nearly 35%.
With this in mind, let's consider if this high-risk, high-reward biotech is worth a deeper look ahead of this forthcoming data readout for Mydicar.
a lot sooner than we all think. GLTA
Please mark this post. GLTA
Shorting a company that has found a way for breast cancer patients to NOT have a biopsy? BIOC allows a simple blood work to do the job rather than a biopsy. You short that kind of a company? Are you kidding me? You will cover tomorrow above $5 if you are fast. Mark this post.
unable to keep it below $10 any longer. Please mark this post and GLTA.
it is scary. It apparently began with endoscopy procedure in patients at a hospital in CA. NSPH in the right place and right time to fight this Super Bug. Going much higher IMHO. God Bless All.
this stock being in triple digits by June/July 2015 when phase III data on cure for blindness is released. Keep in mind FDA was so impressed with Phase I data that it granted ONCE a special status, etc.
I love this company because it is helping humanity. Let's have a constructive conversation about this company and its bright future. God Bless and good luck to all.
a take over target by Apple or the like, then all bets are off. IMHO.
Learn to read between the lines. Apple's cook sending a tweet wishing CEO good luck while he was being interviwed on CNBC spoke volume. Good luck longs. With only 12.5 million in float, see you in triple digits soon...very soon.
Listen loser SHORT, and listen good: Go to ASCO site and you will see the article there. Google it and it will right up. Can you read?
You will be covering above $50 by noon (if not sooner) tomorrow--Monday, December 29, 2014. Sleep well.
FDA Grants Breakthrough Therapy Designation to Investigational CAR T-Cell Therapy
By The ASCO Post
December 15, 2014, Volume 5, Issue 20
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to JCAR015, an investigational chimeric antigen receptor therapy developed by Juno Therapeutics. The designation applies for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia and was filed by Juno’s collaboration partner, Memorial Sloan Kettering Cancer Center, where phase I clinical trials are currently underway.
JCAR015 is currently being tested in clinical trials at Seattle Children’s Hospital for relapsed/refractory CD19-positive pediatric leukemia and at Fred Hutchinson Cancer Research Center for refractory chronic lymphocytic leukemia, non-Hodgkin lymphoma, and acute lymphoblastic leukemia. Data on these programs will be presented at the 54th Annual Meeting of the American Society of Hematology meeting next week in San Francisco.
The FDA’s Breakthrough Therapy designation was created to help accelerate the development and review of new drugs for serious or life-threatening conditions. The designation comes with potential benefits, including intensive FDA guidance and eligibility for priority
is what market needs right now. In my opinion, ECRY is in the right place at the right time. Just my opinion. I am a very small share holder. would love to hear your comments. God Bless.
this concern that corporate america has. I am a very small share holder. I am optimistic. Looking forward to your comments. God Bless.